Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study

Table 1 Patient characteristics

Characteristics	No. of patients
Median age (range)	56 yr (29-69)
Sex
Male	9
Female	5
Performance (ECOG)
0-1	12
2	2
CEA (ng/mL)
< 5	3
≥ 5	11
Primary site
Colon	8
Rectum	6
Sites of metastasis
Liver	7
Lung	8
Lymph nodes	7
Peritoneum	3
Others	2
Number of metastasis
1	3
≥ 2	11
Adjuvant chemotherapy
Yes	9
No	5

CEA: Carcinoembryonic antigen.

Table 2 Toxicity (n = 14)

	NCI-CTC grade
	1	2	3	4
Hematological
Anemia	7	3
Leukopenia	2	2	2
Neutropenia		3	4	1
Thrombocytopenia	1	3	1
Non-hematological
Nausea/vomiting	2	1
Mucositis	1
Diarrhea		2
Proteinuria	1	2
Hematuria	1		1
Asthenia		4